Article No
K0213-3
Anti-TLR9 (CD289) (Human) mAb
Anti-TLR9 (CD289) (Human) mAb
Antibodies Primary
Specifications
| Application | FC |
| Article No | K0213-3 |
| Country Availability | SE, FI, DK, NO, IS, EE, LV, LT, FO, GL |
| Clone | 5G5 |
| Clone Type | monoclonal |
| Concentration | 1 mg/mL |
| Conjugation | Unconjugated |
| Description | Anti-TLR9 (CD289) (Human) mAb |
| Supplier | MBL |
| Immunogen | Recombinant human TLR9 (1-815 a.a.) |
| Isotype | IgG2a |
| Notes | Toll, a Drosophila receptor molecule with extracellular leucine-rich repeat (LRR), has a role in triggering innate defense against bacteria or fungi. Toll-like receptor 9 (TLR9) is a member of TLR family. Members of the TLR family are components of the mammalian anti-microbial response, signaling with a domain closely related to that of IL-1 receptors. Recognition by innate immune cells of the pathogen associated molecular patterns (PAMPs) bacterial CpG-DNA depends on TLR9. TLR9 is dispersedly and intracellularily expressed in resting cells. Upon CpG ODN treatment, TLR9 is recruited to endosome and initiates signal transduction, which activates mitogen-activated protein kinases (MAPKs) and NF-ĸB through the MyD88/IRAK/TRAF6 kinases cascade. |
| Product Type | Antibodies Primary |
| Shipping Information | 4°C |
| Size | 100 µg |
| Source / Host | mouse |
| Species Reactivity | human, mouse |
| Stability | 1 year |
| Storage | -20°C |
| Substrate / Buffer | 1.0 mg/mL in PBS/50% glycerol, pH 7.2 |
| Technical Specifications | Toll, a Drosophila receptor molecule with extracellular leucine-rich repeat (LRR), has a role in triggering innate defense against bacteria or fungi. Toll-like receptor 9 (TLR9) is a member of TLR family. Members of the TLR family are components of the mammalian anti-microbial response, signaling with a domain closely related to that of IL-1 receptors. Recognition by innate immune cells of the pathogen associated molecular patterns (PAMPs) bacterial CpG-DNA depends on TLR9. TLR9 is dispersedly and intracellularily expressed in resting cells. Upon CpG ODN treatment, TLR9 is recruited to endosome and initiates signal transduction, which activates mitogen-activated protein kinases (MAPKs) and NF-ĸB through the MyD88/IRAK/TRAF6 kinases cascade. |
| Product Page Updated | 2023-12-29T16:20:16.638Z |
